On July 9, 2025 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, reported that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies (Press release, Biocytogen, JUL 9, 2025, View Source [SID1234654317]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Prior to this licensing agreement, BeOne Medicines had obtained a license to use Biocytogen’s RenMice fully human antibody platform. Building on this established collaboration, the new agreement expands the partnership into antibody license, further strengthening the strategic relationship between the two companies.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, "BeOne Medicines is a global leader in drug development, and we are thrilled to enter into this strategic collaboration. The antibodies licensed under this agreement were discovered using our proprietary RenMice fully human antibody platform, highlighting our ability to empower partners in driving innovative drug discovery. We look forward to seeing these promising molecules progress rapidly into the clinic and ultimately bring transformative treatment options to patients worldwide."
Under the terms of the agreement, Biocytogen will receive an upfront payment from BeOne Medicines. In addition, Biocytogen is eligible to receive development and regulatory milestone payments, commercial milestone payments, and tiered royalties based on future net sales of licensed products.